Wilms' Tumor Clinical Trials

A listing of Wilms' Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
featured
AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

  • 316 views
  • 08 Nov, 2020
  • 1 location
Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

effective in treating Wilm's tumor. PURPOSE: Phase III trial to study the effectiveness of chemotherapy before and after surgery in treating children who have Wilm's tumor.

nephroblastoma
tumor cells
conventional surgery
cyclophosphamide
  • 9 views
  • 07 Nov, 2020
  • 1 location
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger

  • 23 views
  • 28 Jan, 2021
  • 1 location
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

  • 0 views
  • 14 Mar, 2021
  • 1 location
DC Vaccination in CML

from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine

tyrosine
bcr-abl protein
remission
leukemia
residual tumor
  • 6 views
  • 22 Jan, 2021
  • 2 locations
Next Generation Sequencing NGS Monitors Minimal Residual Disease MRD in Allo-PBSCT Patients

Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation. Overview of study design. This study is a single-center, single-arm, prospective clinical trial designed to evaluate the significance of next generation gene sequencing (NGS) in …

  • 0 views
  • 23 Jan, 2021
  • 1 location
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms

  • 0 views
  • 31 Jul, 2021
  • 60 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

measurable disease
recurrent disease
neulasta
alpha-fetoprotein
beta human chorionic gonadotropin
  • 997 views
  • 01 Aug, 2021
  • 114 locations
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study …

fibrosarcoma
experimental drug
solid tumor
kidney function test
NTRK
  • 1310 views
  • 27 Jul, 2021
  • 79 locations
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH

cell transplantation
colony stimulating factor
myelodysplastic syndromes
myeloid leukemia
granulocyte colony stimulating factor
  • 53 views
  • 07 Nov, 2020
  • 1 location